Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today

HIMS Cover Image

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE: HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, and EBITDA came in a bit short, but revenue soared year over year, easily beating Wall Street's forecasts. This jump came from surging demand in the weight-loss business, which remains a key growth engine. 

That said, EBITDA slightly missed estimates, and gross margin fell from 83% to 77%, signaling rising costs to attract and serve customers. 

Looking ahead, Hims & Hers provided optimistic guidance, projecting full-year 2025 revenue and adjusted EBITDA well above analysts' expectations. 

Overall, we think this was still a solid quarter with some key areas of upside, but the worse-than-anticipated customer additions and EBITDA seem to be sending shares lower. We also note that expectations were high going into the print as the stock was up 104% year-to-date before the announcement.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 73 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business. 

The previous big move we wrote about was 4 days ago when the stock dropped 24% on the news that U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as Wegovy and Ozempic has ended. This could lead to lower sales for companies like Hims & Hers Health, which sell weight-loss medications through their platform.

Hims & Hers Health is up 58.2% since the beginning of the year, but at $39.86 per share, it is still trading 42% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $3,947.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.65
+0.79 (0.39%)
AAPL  259.36
-1.22 (-0.47%)
AMD  201.31
-2.06 (-1.02%)
BAC  52.15
-0.62 (-1.17%)
GOOG  310.12
+6.56 (2.16%)
META  646.35
+1.57 (0.24%)
MSFT  396.88
-1.58 (-0.40%)
NVDA  187.93
+0.03 (0.02%)
ORCL  151.46
-5.08 (-3.25%)
TSLA  409.90
-1.81 (-0.44%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.